{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T18:10:21Z","timestamp":1747159821180,"version":"3.40.5"},"reference-count":9,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T00:00:00Z","timestamp":1651708800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.ekir.2022.05.002","type":"journal-article","created":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T07:59:47Z","timestamp":1652428787000},"page":"1917-1921","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Interferon-\u03b21a-Induced Thrombotic Microangiopathy: Possible Implication of the Alternative Pathway of the Complement"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1442-9716","authenticated-orcid":false,"given":"Maxime","family":"Taghavi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Stordeur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Collart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Dachy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnieszka","family":"Pozdzik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Do Carmo Filomena","family":"Mesquita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\u00eblle","family":"Nortier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2022.05.002_bib1","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.kint.2016.10.005","article-title":"Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) Controversies Conference","volume":"91","author":"Goodship","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2022.05.002_bib2","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1053\/j.ajkd.2015.03.040","article-title":"Glomerular diseases dependent on complement activation, including atypical hemolytic uremic syndrome, membranoproliferative glomerulonephritis, and C3 glomerulopathy: core curriculum 2015","volume":"66","author":"Noris","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2022.05.002_bib3","doi-asserted-by":"crossref","first-page":"e01930","DOI":"10.1002\/brb3.1930","article-title":"A\u00a0case report of late-onset atypical hemolytic uremic syndrome during interferon beta in multiple sclerosis: open issues in literature review","volume":"11","author":"Parisi","year":"2021","journal-title":"Brain Behav"},{"key":"10.1016\/j.ekir.2022.05.002_bib4","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1056\/NEJMcps1606750","article-title":"After the party\u2019s over","volume":"376","author":"George","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2022.05.002_bib5","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.thromres.2018.01.039","article-title":"Endothelial cell functions impaired by interferon in\u00a0vitro: insights into the molecular mechanism of thrombotic microangiopathy associated with interferon therapy","volume":"163","author":"Jia","year":"2018","journal-title":"Thromb Res"},{"key":"10.1016\/j.ekir.2022.05.002_bib6","doi-asserted-by":"crossref","first-page":"a032003","DOI":"10.1101\/cshperspect.a032003","article-title":"Interferon \u03b2 for multiple sclerosis","volume":"8","author":"Jakimovski","year":"2018","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.ekir.2022.05.002_bib7","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1159\/000045147","article-title":"Hemolytic uremic syndrome associated with beta-interferon therapy for chronic hepatitis C","volume":"80","author":"Ubara","year":"1998","journal-title":"Nephron"},{"key":"10.1016\/j.ekir.2022.05.002_bib8","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/ckj\/sfw143","article-title":"Thrombotic microangiopathy induced by interferon beta in patients with multiple sclerosis: three cases treated with eculizumab","volume":"10","author":"Allinovi","year":"2017","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ekir.2022.05.002_bib9","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1182\/blood-2016-05-715987","article-title":"Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculature","volume":"128","author":"Kavanagh","year":"2016","journal-title":"Blood"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024922013778?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024922013778?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T20:51:45Z","timestamp":1719435105000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024922013778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":9,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S2468024922013778"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2022.05.002","relation":{},"ISSN":["2468-0249"],"issn-type":[{"type":"print","value":"2468-0249"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interferon-\u03b21a-Induced Thrombotic Microangiopathy: Possible Implication of the Alternative Pathway of the Complement","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2022.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}